| 摘要 |
New human opioid-type receptor-1 (OTR1) gene (I) of 4980 base pairs, including 5' and 3'-untranslated regions, reproduced. Independent claims are also included for the following: (a) transcription factors, RNA polymerases, pharmaceuticals and chemicals that modify, positively or negatively, expression of (I); (b) mRNA transcribed from (I), including splice variants and isoforms; (c) cDNA derived from the mRNA, or the intronless version of (I); (d) protein (II), and its derived peptides, derived or produced from (I), its cDNA or mRNA; (e) (monoclonal) antibodies and antisera raised against (II) or one or more of its epitopes; (f) expression systems that produce natural or recombinant (II); (g) ligand-binding studies and screening assays on native or recombinant receptors, or cells or cell membranes that contain them; (h) transgenic and knockout animals which express (II), or their splice variants, at altered levels or not at all; (i) gene therapy methods (and their development or use) based on (II) and the corresponding gene, mRNA or cDNA; and (j) (anti)sense oligonucleotides derived from (I) and their use; and (k) diagnosis and treatment of diseases that are (in)directly associated with (II). In all cases, the protein, gene, mRNA or cDNA can be modified, e.g. by amino acid or base exchanges.
|
